ClearPoint Neuro officer nets shares from RSU vesting

ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall reported vesting of 8,856 restricted stock units, which were settled into an equal number of shares of common stock at a stated price of $0.0000 per share on March 3, 2026.

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall reported vesting of 8,856 restricted stock units, which were settled into an equal number of shares of common stock at a stated price of $0.0000 per share on March 3, 2026.

In connection with this vesting, 4,506 shares of common stock were delivered to ClearPoint Neuro at $8.84 per share to cover tax withholding obligations. Following these transactions, Stigall held 35,424 restricted stock units and 76,706 shares of common stock, all reported as directly owned.

Insider Trade Summary

8,856 shares exercised/converted

Exercise 3 txns

Insider STIGALL L. JEREMY

Role Chief Business Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	8,856	$0.00	$0.00
Exercise	Common Stock	8,856	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,506	$8.84	$40K

Holdings After Transaction: Restricted Stock Units — 35,424 contracts (Direct); Common Stock — 76,706 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CLPT’s Chief Business Officer report on March 3, 2026?

L. Jeremy Stigall reported settlement of 8,856 restricted stock units into common stock and a related tax-withholding share delivery. These actions reflect routine equity compensation vesting and associated tax settlement using 4,506 shares at a reported price of $8.84 per share.

How many ClearPoint Neuro (CLPT) restricted stock units vested for the Chief Business Officer?

8,856 restricted stock units vested for L. Jeremy Stigall, each representing one share of ClearPoint Neuro common stock. The units were settled in shares on their scheduled vesting date, increasing his directly owned common stock before the tax-withholding share delivery.

How many CLPT shares were used to cover taxes from the RSU vesting?

4,506 shares of ClearPoint Neuro common stock were delivered to the company to satisfy tax withholding obligations. The shares are reported at a transaction price of $8.84 per share and are associated with the vesting of restricted stock units held by the Chief Business Officer.

What are L. Jeremy Stigall’s ClearPoint Neuro share holdings after these Form 4 transactions?

After the reported transactions, L. Jeremy Stigall directly held 76,706 shares of ClearPoint Neuro common stock and 35,424 restricted stock units. These figures reflect the RSU settlement into shares and the tax-withholding share delivery reported as of March 3, 2026.

Were the March 3, 2026 CLPT insider transactions open-market buys or sells?

The transactions were classified as an exercise or conversion of derivative securities and a tax-withholding disposition, not open-market buys or sells. Restricted stock units converted into common shares, and some shares were delivered to ClearPoint Neuro to cover the related tax obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STIGALL L. JEREMY

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		8,856	A	(1)	81,212	D
Common Stock	03/03/2026		F		4,506(2)	D	$8.84	76,706	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/03/2026		M			8,856	(1)	(1)	Common Stock	8,856	(1)	35,424	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Jeremy L. Stigall	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.